Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

Gynecologic Oncology Reports(2020)10.1016/j.gore.2020.100554Source: DataRank Database

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma is a research paper published in Gynecologic Oncology Reports (2020). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: goldTopics (12)IDs (PubMed, PMC)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Natália Buza ORCID,Pei Hui,Stefania Bellone ORCID,Burak Zeybek ORCID,Elena Ratner ORCID

Live enrichment

PubMed:32140533 PMC:PMC7049633

NIH

Grant: U01 CA176067-01A1

NCATS NIH HHS

Grant: UL1 TR001863

NCI NIH HHS

Grant: U01 CA176067

National Institutes of Health

Grant: 1U01CA176067-01A1

Integrated genomic analysis of racial disparities in endometrial cancer

goldLicense: cc-by-nc-nd

publisherhttps://doi.org/10.1016/j.gore.2020.100554

publisherhttps://api.elsevier.com/content/article/PII:S2352578920300205?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2352578920300205?httpAccept=text/plain

repositoryhttps://doaj.org/article/ff2bcf379200416db1549409a4ed7de8

Europe_PMChttps://europepmc.org/articles/PMC7049633

Fields of Study

03 medical and health sciences0302 clinical medicine

Keywords

HER2/neuTrastuzumabRecurrentTreatment-resistantUterine Serous CarcinomaRG1-991Neoplasms. Tumors. Oncology. Including cancer and carcinogensCase ReportGynecology and obstetricsRC254-282

Sustainable Development Goals

SDG 3: 3. Good health

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

FAIR Checklist

Authors (9)

Funding (4 grants)

Open Access

Topics

Annotations (Europe PMC)